An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC)
on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with
This is an international, multicenter, event-driven, randomized, double-blind, parallel
group, placebo-controlled study, evaluating the utility of SZC versus placebo to reduce the
incidence of sudden cardiac death (SCD), stroke, and arrhythmia-related hospitalizations,
interventions, and emergency department (ED) visits in participants on chronic hemodialysis
with recurrent hyperkalemia.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.